Meeting
2019 ASCO Annual Meeting
Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs).
Authors
Enrique Aranda
IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III/ Spain, Córdoba, Spain
Enrique Aranda , Pilar Garcia-Alfonso , Jose María Vieitez , Maria Jose Ortiz , Carlos López-López , Juan José Reina-Zoilo , Antonieta Salud Salvia , Guillermo Alfonso Quintero Aldana , Luis Robles , Maria Jose Safont , Adelaida La Casta Munoa , Inmaculada Alés , Eduardo Polo Marques , Javier Gallego Plazas , Beatriz García de Paredes , Rafael Lopez , Guillot Mónica , Manuel Valladares-Ayerbes , Javier Sastre , Eduardo Díaz-Rubio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
2012-000840-90
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3549)
DOI
10.1200/JCO.2019.37.15_suppl.3549
Abstract #
3549
Poster Bd #
41
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase II trial of target-guided personalized chemotherapy in first-line metastatic colorectal.
First Author: Antonio Cubillo
Poster
2023 ASCO Annual Meeting
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.
First Author: Anna Maria Rachiglio
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
First Author: Takeshi Yamada
Poster
2017 Gastrointestinal Cancers Symposium
Tumor mutational burden of microsatellite stable metastatic colorectal tumors by patient factors and KRAS, BRAF, and PIK3CA mutation status.
First Author: Jun Gong